Latest News
-
RAHWAY, N.J. — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the pivotal Phase 3 TroFuse-015 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) licensed from Kelun-Biotech, met its primary endpoint of overall survival (OS) compared to treatment of physician’s...
-
PLAINSBORO, N.J. — Novo Nordisk today announced that the US Food and Drug Administration (FDA) approved once-weekly Sogroya® (somapacitan-beco) injection (5 mg, 10 mg, or 15 mg) for children aged 2.5 years and older with growth failure associated with Turner Syndrome (TS), a chromosomal condition affecting development in females that commonly leads...
-
WAYNE, Pa. — Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced QTORIN™ docetaxel, a new QTORIN™ program...
